Rigshospitalet — Sponsor Intelligence | 94 EU Trials

Filter these 94 trials by condition, phase, country and more.

Open in Search →

94 Registered trials

54 Recruiting

26 Completed trials

12 Countries active

144 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 15 Phase II: 31 Phase I/II: 3 Phase III/IV: 4 Phase IV: 35 Phase I: 1 Phase I (Other): 4 Phase I (FiH): 1

Oversight events:

3 serious breaches 3 temporary halts 1 urgent safety measure 1 unexpected event across 6 trials

View oversight register →

100%

26 of 26 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Pulmonary embolism 2 Neuroendocrine carcinoma metastatic 2 Neuroendocrine carcinoma 2 Breast cancer 1 Coma 1 Glioma 1 HER2 protein overexpression 1 Measles 1 Post-traumatic headache 1 Acute myeloid leukaemia 1 Antiphospholipid antibodies 1 Brain scan normal 1

Top IMPs

SODIUM CHLORIDE 12 SEMAGLUTIDE 5 (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE 3 DEXAMETHASONE DISODIUM PHOSPHATE 3 FLUDEOXYGLUCOSE (18F) 3 APOMORPHINE HYDROCHLORIDE HEMIHYDRATE 2 ATEZOLIZUMAB 2 CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS 2 DEXAMETHASONE PHOSPHATE 2 DICLOFENAC SODIUM 2 DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL 2 DUPILUMAB 2

All trials — page 4

94 total

[68Ga]Ga-FAPI total body PET/CT for improving diagnostic sensitivity and preoperative staging in gastroesophageal cancer and pancreatic canc… Ended

2023-503632-41-01 Phase II 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
Biologic treatment of rhinosinusitis with nasal polyposis in real-world Danish patients - a direct comparison of dupilumab and mepolizumab Ended

2022-502250-14-00 Phase IV 1 country DUPILUMAB; MEPOLIZUMAB; MOMETASONE FUROATE; PREDNISOLONE
The RESCUE study Ended

2024-518272-30-00 Phase IV 1 country HYDROCORTISONE
The Nordic Aortic Valve Intervention Trial 4 (NOTION-4) Ended

2024-518547-38-00 Phase IV 1 country
Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis Ended

2024-514287-84-00 Phase III 1 country OCRELIZUMAB; RITUXIMAB
Perineural incobotulinumtoxin-A for Complex Regional Pain Syndrome - An open-label feasibility study (PINCom) Halted

2024-519832-17-00 Phase II 1 country CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS
Prevention of agitation and pain after anaesthesia in children less than or equal to 1 year Halted

2024-520075-28-01 Phase II 1 country CLONIDINE HYDROCHLORIDE
Ephedrine 0.15 mg/kg for reducing onset time of rocuronium 0.6 mg/kg in elderly patients. Ended

2024-517933-42-00 Phase IV 1 country EPHEDRINE HYDROCHLORIDE
ARETHA: cARdiomems vEriciguaT Heart fAilure (A double-blind randomized placebo-controlled trial of vericiguat in heart failure patients with… Ended

2024-514111-10-00 Phase IV 1 country VERICIGUAT
Is dermal measles-mumps-rubella-vaccine administration better than regular injection? Ended

2023-503845-79-01 Phase II 1 country RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) PRODUCED IN WI-38 HUMAN D…
A blinded randomized study of two types of reversal agents (neostigmine/glycopyrrolate 50 mikrogram/kg or sugammadex 2 mg/kg) for reversal o… Ended

2023-504230-21-00 Phase IV 1 country GLYCOPYRRONIUM BROMIDE, NEOSTIGMINE METHYLSULFATE; SUGAMMADEX
Comparison of cocaine, lidocaine/xylometazoline and saline for intranasal analgesia - A blinded triple crossover study Ended

2023-506644-17-01 Phase III 1 country LIDOCAINE HYDROCHLORIDE; SODIUM CHLORIDE; XYLOMETAZOLINE HYDROCHLORIDE
The GOBLET trial: A clinical trial on GOblet cell density after Benzalkonium chloride and preservative-free Latanoprost Eye drop Treatment Ended

2024-512275-12-00 Phase IV 1 country LATANOPROST
EMPagliflozin after Aortic Valve Replacement - the EMPAVR study Ended

2023-504731-40-01 Phase IV 1 country EMPAGLIFLOZIN
68Ga satoreotide trizoxetan PET/CT in patients with high grade neuroendocrine lung cancer Ended

2023-503362-24-01 Phase II 1 country SATOREOTIDE TRIZOXETAN GALLIUM GA-68
Dapagliflozin in Pulmonary Arterial Hypertension (DAPAH) Ended

2024-518551-37-00 Phase II 1 country DAPAGLIFLOZIN
Dual action weight loss in IIH - IIHDUAL Ended

2024-517120-19-02 Phase IV 1 country SEMAGLUTIDE
TEMPLE - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy Ended

2024-517307-37-00 Phase I (FiH) 1 country ATEZOLIZUMAB
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM) Ended

2024-517128-21-02 Phase IV 1 country DICLOFENAC POTASSIUM; RIMEGEPANT
LOW-DOSE DOBUTAMINE INFUSION AND SINGLE-DOSE TOCILIZUMAB IN ACUTE MYOCARDIAL INFARCTION PATIENTS WITH HIGH RISK OF CARDIOGENIC SHOCK DEVELOP… Ended

2024-515999-13-00 Phase IV 1 country DOBUTAMINE; TOCILIZUMAB
Steroids and/ or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy. (SNAP) Ended

2024-511820-15-03 Phase IV 1 country DEXAMETHASONE PHOSPHATE; DICLOFENAC SODIUM
Cluster randomised trial of blood thinners Ended

2022-502402-32-00 Phase IV 1 country

Showing 73–94 of 94 trials

← All sponsors A–Z